Drug intelligence / Profile preview

BMS-986325

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

BMS-986325 is a fully human monoclonal antibody targeting CD40, developed by Bristol Myers Squibb for the treatment of primary Sjögren's syndrome. It acts as a CD40 antigen inhibitor and belongs to the class of anti-inflammatories and antirheumatics. The drug is being investigated primarily for its immunomodulatory effects in autoimmune diseases, with its main mechanism involving inhibition of the CD40 pathway—a key regulator in immune cell activation and inflammation[2][3][5].

Other names: BMS 986325BMS986325BMS-986325Y 12XX-HZ28-P238KY12XX-HZ28-P238KY-12XX-HZ28-P238K

Targets

CD40 (Cluster of differentiation 40 receptor)

Beyond the preview

Go deeper on BMS-986325.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986325.

Explore the full profile